| Market Cap | 1.64M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -374.47k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 14.28k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -59.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -89.00% |
| Recommedations | - | Quick Ratio | 0.04 | Shares Outstanding | 1.10B | 52W Low Chg | 54.00% |
| Insider Own | 2.37% | ROA | -153.58% | Shares Float | 0.98B | Beta | -4.76 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00077 |
| Gross Margin | 9.95% | Profit Margin | - | Avg. Volume | 3,169,961 | Target Price | - |
| Oper. Margin | -8,196.55% | Earnings Date | - | Volume | 1,056,110 | Change | 10.00% |
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.
